Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial.
Volkmann ER, Kreuter M, Hoffmann-Vold AM, Wijsenbeek M, Smith V, Khanna D, Denton CP, Wuyts WA, Miede C, Alves M, Sambevski S, Allanore Y. Volkmann ER, et al. Among authors: miede c. Rheumatology (Oxford). 2022 Nov 2;61(11):4397-4408. doi: 10.1093/rheumatology/keac091. Rheumatology (Oxford). 2022. PMID: 35150246 Free PMC article. Clinical Trial.
Risk of Malnutrition in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease Treated With Nintedanib in the Randomized, Placebo-Controlled SENSCIS Trial.
Volkmann ER, McMahan ZH, Smith V, Jouneau S, Miede C, Alves M, Herrick AL; SENSCIS Trial Investigators. Volkmann ER, et al. Among authors: miede c. Arthritis Care Res (Hoboken). 2023 Dec;75(12):2501-2507. doi: 10.1002/acr.25176. Epub 2023 Aug 7. Arthritis Care Res (Hoboken). 2023. PMID: 37357024 Clinical Trial.
Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score.
Kuwana M, Allanore Y, Denton CP, Distler JHW, Steen V, Khanna D, Matucci-Cerinic M, Mayes MD, Volkmann ER, Miede C, Gahlemann M, Quaresma M, Alves M, Distler O. Kuwana M, et al. Among authors: miede c. Arthritis Rheumatol. 2022 Mar;74(3):518-526. doi: 10.1002/art.41965. Epub 2022 Feb 13. Arthritis Rheumatol. 2022. PMID: 34514739 Free PMC article. Clinical Trial.
Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial.
Berry NC, Mauri L, Steg PG, Bhatt DL, Hohnloser SH, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, Ten Berg JM, Cannon CP. Berry NC, et al. Among authors: miede c. Circ Cardiovasc Interv. 2020 Apr;13(4):e008349. doi: 10.1161/CIRCINTERVENTIONS.119.008349. Epub 2020 Apr 7. Circ Cardiovasc Interv. 2020. PMID: 32252548 Free article. Clinical Trial.
Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial.
Nicolau JC, Bhatt DL, Hohnloser SH, Kimura T, Lip GYH, Miede C, Nordaby M, Oldgren J, Steg PG, Ten Berg JM, Godoy LC, Cannon CP; RE-DUAL PCI Steering Committee and Investigators. Nicolau JC, et al. Among authors: miede c. Drugs. 2020 Jul;80(10):995-1005. doi: 10.1007/s40265-020-01323-x. Drugs. 2020. PMID: 32562206 Free PMC article. Clinical Trial.
Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial.
Peterson BE, Bhatt DL, Gabriel Steg P, Oldgren J, Maeng M, Zeymer U, Halvorsen S, Hohnloser SH, Lip GYH, Kimura T, Nordaby M, Miede C, Kleine E, Ten Berg JM, Cannon CP; RE-DUAL PCI Steering Committee and Investigators. Peterson BE, et al. Among authors: miede c. JACC Cardiovasc Interv. 2021 Apr 12;14(7):768-780. doi: 10.1016/j.jcin.2021.02.022. JACC Cardiovasc Interv. 2021. PMID: 33826497 Free article. Clinical Trial.
Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI.
De Caterina R, Procopio A, Lopez Sendon JL, Raev D, Mehta SR, Opolski G, Oldgren J, Steg PG, Hohnloser SH, Lip GYH, Kimura T, Kleine E, Ten Berg JM, Bhatt DL, Miede C, Nordaby M, Cannon CP; RE-DUAL PCI Steering Committee and Investigators. De Caterina R, et al. Among authors: miede c. Am J Med. 2020 Nov;133(11):1302-1312. doi: 10.1016/j.amjmed.2020.03.045. Epub 2020 May 7. Am J Med. 2020. PMID: 32389658 Free article. Clinical Trial.
22 results